Skip to content
About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
November 13, 2025
Vaxart to Host Upcoming Conference Calls
November 7, 2025
Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program
November 5, 2025
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
October 8, 2025
Vaxart Appoints W. Mark Watson as Lead Independent Director
September 17, 2025
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
September 10, 2025
Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025
September 3, 2025
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
September 2, 2025
Vaxart, Inc. Stockholder Fireside Chat
August 21, 2025
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
←
Previous Page
1
2
3
4
5
Next Page
→
